CD8A and neoplasm: On the other hand, immune checkpoint inhibitors, for instance anti-PD-1 and anti-PD-L1, can suppress the expression level of SLC7A11 and GPX4 on tumors, activate CD8+ T cells in tumor microenvironment, and enhance the release of IFN-γ.